STRategies in Early Arthritis Management
Completed
- Conditions
- Polyarthritis/rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritis
- Registration Number
- ISRCTN56637846
- Lead Sponsor
- Jan van Breemen Institute (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1. Aged 18+ years
2. Symptom duration less than 3 years
3. Swelling in two to five joints
Exclusion Criteria
1. Earlier treatment with disease modifying antirheumatic drugs except hydroychloroquine
2. Prednisone use within 3 months
3. Bacterial arthritis, crystal induced arthritis, reactive arthritis, sarcoidosis, osteoarthritis or systemic autoimmune disease other than rheumatoid arthritis (RA)
4. Pregnancy
5. Erosive disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression of radiographic damage score after 2 years.
- Secondary Outcome Measures
Name Time Method 1. Functional capacity<br>2. Quality of life<br>3. Disease activity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted in STRategies for early rheumatoid arthritis management (ISRCTN56637846)?
How does the STRategies trial compare to standard DMARDs in treating polyarthritis subtypes?
Which biomarkers correlate with treatment response in ISRCTN56637846 early arthritis intervention?
What adverse events were reported in Jan van Breemen Institute's STRategies interventional trial?
Are there combination therapies or novel drug classes evaluated alongside STRategies for rheumatoid arthritis?